Skip to content

DR. DEWITTE EN DR. SUNAERT

Active
Private limited companyfounded 2001active for 25 yearsKloosterdreef(O) 11, 8710 Wielsbeke, BelgiumKBO/BCE: BE 0474.155.992

From the official registers: KBO 25 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

DR. DEWITTE EN DR. SUNAERT has been active since 2001 and the Belgian Official Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €1.1m and a net result of €101,865. Equity has been growing by about 14% per year since 2019. Its solvency ranks better than 95% of 399 sector peers (NACE 86, financial year 2026). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow ReportCompare
DR. DEWITTE EN DR. SUNAERTActiveChecked score 94/100
Risk analysis ReportCompare

Overview

Official details

KBO
Status
Active since 22-02-2001 Normal situation
Legal form
Private limited company
Registered office
Kloosterdreef(O) 11, 8710 Wielsbeke
Activity
General medical practice NACE 86210and 2 others
Establishment unit
2.228.748.016 8710 Wielsbeke, since 14-02-2001
Financial year end
31 March
Peppol
Reachable since 16-10-2025
Company details

Board and ownership

Board
  • Dewitte PaulDirector
  • Sunaert PatriciaDirector
Board & ownership

Financial position

94 Excellent Checked score 2026
Bankruptcy probabilitywithin 12 months
< 0.1%
Annual accounts to 31-03-2026
Gross margin
€181,844
▼ 22.1%
Turnover
≈ €330,000
estimated
Profit
€101,865
▼ 16.4%
Equity
€1.1m
▲ 10.6%
Total assets
€1.1m
▲ 9.4%
2026 accounts filed 8 days before the deadline
Filed on 23-10-2026at the National Bank
Financials
Score breakdownlowers riskSector: Human health activities (NACE 86)Size: total assets €1.1mEquity €1.1m (98.6% of total assets)Figures for financial year 2026 (filed on 27-10-2026)Show the evidence

Checked score

Score 2026
94 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 51% of micro companies in human health (NACE 86)
Every signal that counts is listed under Signals.
Financial strength · tick: 2025
Strong
Solvency 100=
equity 98.6% of total assets
Liquidity 62+10
short-term debt 1.4% · cash 9.7%
Profitability 81-3
return on assets 9.5%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,155 companies, NACE 86, micro)
Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025lowest value 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026highest value 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026
Credit of up to €95,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 60.91 (31.96 in 2025), above the usual 1.5. Short-term debt is 1.4% and cash 9.7% of total assets. 1.4% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 40% on liquidity, 27% on profitability and 53% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Size: total assets €1.1m
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
lowers risk · Equity €1.1m (98.6% of total assets)
NBB · annual accounts
lowers risk · Figures for financial year 2026 (filed on 27-10-2026)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2026 was due by 31-10-2026 and was filed on 23-10-2026, 8 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2026
8 days early
2025
8 days early
2024
14 days early
2023
26 days early
2022
4 days early
2021
6 days early
2020
2 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 10 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-03-2027 and is due by 31-10-2027. Nothing is late today. The company usually files around 23 October (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
01-11-2026 today31-03-2027 year end31-10-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Positive: Higher solvency than 95% of companies in human healthsector median 71.6% · 399 companies 98.6% View
  • Positive: Filed on time since financial year 2019accounts within the deadline every year 8 years View
  • Positive: 8 profitable years in a rowprofit 2026: €101,865 8 years View

Documents

Annual accounts at the NBB

All 25 annual accounts

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about DR. DEWITTE EN DR. SUNAERT

What is the company number of DR. DEWITTE EN DR. SUNAERT?
The company number of DR. DEWITTE EN DR. SUNAERT is 0474.155.992. The VAT number is the same number with BE in front: BE 0474.155.992.
Where is DR. DEWITTE EN DR. SUNAERT based?
The registered office is at Kloosterdreef(O) 11, 8710 Wielsbeke.Company details
What does DR. DEWITTE EN DR. SUNAERT do?
According to the KBO register, the main activity is general medical practice (NACE 86210).
What is the legal form of DR. DEWITTE EN DR. SUNAERT?
The legal form of DR. DEWITTE EN DR. SUNAERT is Private limited company (BV).
When was DR. DEWITTE EN DR. SUNAERT founded?
DR. DEWITTE EN DR. SUNAERT was founded on 22-02-2001.
Is DR. DEWITTE EN DR. SUNAERT still active?
Yes, DR. DEWITTE EN DR. SUNAERT is an active enterprise in the KBO register.
How many employees does DR. DEWITTE EN DR. SUNAERT have?
DR. DEWITTE EN DR. SUNAERT had an average of 0.2 full-time equivalents in financial year 2020, according to the filed annual accounts.Financials
What is the turnover of DR. DEWITTE EN DR. SUNAERT?
The turnover in financial year 2026 is ≈ €330,000. This figure is estimated from the gross margin of €181,844 and 30 comparable companies (NACE 86210). It probably lies between €260,000 and €410,000.
Is DR. DEWITTE EN DR. SUNAERT profitable?
In financial year 2026, DR. DEWITTE EN DR. SUNAERT made a profit of €101,865.
Where can I find the annual accounts of DR. DEWITTE EN DR. SUNAERT?
DR. DEWITTE EN DR. SUNAERT filed 25 annual accounts with the National Bank of Belgium, the latest for financial year 2026.Annual accounts at the National Bank
When are the next annual accounts of DR. DEWITTE EN DR. SUNAERT due?
DR. DEWITTE EN DR. SUNAERT must file the annual accounts for financial year 2027 by 31-10-2027.Timeline

Comparable companies

These companies have the same main activity as DR. DEWITTE EN DR. SUNAERT: general medical practice (NACE 86210). They are comparable in size and age: total assets between €944,000 and €1.2m, founded between 2001 and 2003.

CompanyTotal assetsGross margin
DR. DEWITTE EN DR. SUNAERT Wielsbeke€1.1m€0.2m
DOKTER LUC PLATTEAU Nieuwpoort€1.1m€0.2m
DR. MICHEL MAHIEU Oostkamp€1.1m€0.2m
Dr. Steven Speecke Kortrijk€1.0m€0.2m
DR. DE MUNTER GREET, huisarts Lede€1.2m€0.2m
DR.AZAIEZ Overijse€0.9m€0.2m
Dr Ogla ALWASH Schaarbeek€1.0m€0.2m
Full comparison

Next steps

Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure